Stock listing

NASDAQ:MNPR Monopar Therapeutics Inc. Stock

Home listing (NASDAQ) of Monopar Therapeutics Inc.

Follow Monopar Therapeutics Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:MNPR

$69.00 USD -1.75 (-2.5%)

Close on Nov 20, 2026

Past year -16.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$67.36 – $69.86 USDNov 20, 2026
Volume
132,610 sharesNov 20, 2026
Market cap
$467.6M USDAt the close on Nov 20, 2026 · price × 6.78M shares outstanding
52-week range
$50.07 – $124.82 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$13.31M USDMedian day 135,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Monopar Therapeutics Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:MNPR · Home$69.00 USD-1.75 (-2.5%)132,610$68.50$69.86$67.36$70.75Close on Nov 20, 2026
Frankfurt:1IY0€62.00 EUR-1.20 (-1.9%)—€62.00€62.10€62.00€63.20Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MNPR · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$69.00-1.75-2.5%$68.50$69.86$67.36132,610
$70.75-0.31-0.4%$70.08$72.79$70.08102,019
$71.06-0.91-1.3%$71.45$72.92$69.79122,983
$71.97-0.030.0%$72.55$75.09$70.34200,030
$72.00-0.68-0.9%$72.93$73.48$67.70203,206
$72.68+0.95+1.3%$70.11$74.69$67.12313,024
$71.73-0.05-0.1%$72.87$72.87$70.80157,459
$71.78-1.97-2.7%$72.45$75.59$70.2188,064
$73.75+2.33+3.3%$74.75$82.51$69.67124,852
$71.42+4.20+6.2%$68.02$72.25$67.4592,947
$67.22-5.59-7.7%$72.45$73.28$66.91157,518
$72.81+2.92+4.2%$70.13$74.02$70.09189,611
$69.89+3.61+5.4%$66.74$70.07$66.29154,089
$66.28-4.04-5.7%$70.02$70.26$65.01218,899
$70.32-1.59-2.2%$71.36$72.76$69.35197,763
$71.91-1.48-2.0%$73.90$75.29$70.65163,098
$73.39+1.55+2.2%$72.04$73.39$69.94187,362
$71.84+1.30+1.8%$72.00$73.99$70.20135,923
$70.54-0.11-0.2%$71.01$71.85$69.3479,014
$70.65-1.93-2.7%$71.84$71.84$69.4895,500
$72.58+0.23+0.3%$71.83$73.13$71.22117,400
$72.35-1.88-2.5%$73.47$75.08$70.9587,300
$74.23+2.76+3.9%$72.20$74.90$71.9586,600
$71.47+2.20+3.2%$70.10$72.32$69.7167,600
$69.27-2.53-3.5%$71.01$71.01$68.81161,600
$71.80-1.30-1.8%$73.20$73.28$70.05140,900
$73.10+1.02+1.4%$70.74$74.01$70.51129,600
$72.08-4.97-6.5%$76.16$76.92$71.66249,900
$77.05-1.91-2.4%$79.30$79.59$75.05128,500
$78.96-5.02-6.0%$83.47$84.04$78.80135,800
$83.98+0.20+0.2%$82.48$85.49$81.27185,500
$83.78+4.21+5.3%$78.28$85.03$77.98107,000
$79.57+1.28+1.6%$78.04$82.66$75.33302,200
$78.29+0.32+0.4%$78.72$79.59$76.24128,300
$77.970.000.0%$78.36$80.00$77.03107,600
$77.97-1.70-2.1%$79.64$80.33$77.59130,800
$79.67-0.33-0.4%$80.00$82.35$79.33226,300
$80.00-3.72-4.4%$82.77$83.04$79.38162,400
$83.72-1.515-1.8%$85.24$86.69$82.92268,200
$85.24-3.605-4.1%$89.58$90.00$85.06105,800
$88.84-0.54-0.6%$88.03$90.05$86.54252,900
$89.38-7.25-7.5%$96.78$96.78$87.5989,300
$96.63+0.91+1.0%$96.60$97.37$94.01136,000
$95.72-0.75-0.8%$97.92$98.19$94.9589,200
$96.47-6.23-6.1%$102.44$102.45$95.96382,800
$102.70+1.25+1.2%$103.33$104.09$98.90206,600
$101.45-2.88-2.8%$105.48$105.49$100.1389,600
$104.33-3.99-3.7%$106.93$106.93$101.8991,800
$108.32-1.94-1.8%$111.99$111.99$107.02106,600
$110.26+0.30+0.3%$113.84$113.84$109.7790,000
$109.96-2.42-2.2%$110.55$112.56$108.8489,500
$112.38-2.00-1.7%$112.31$116.61$112.19110,300
$114.38-3.18-2.7%$115.61$117.61$113.27103,900
$117.56-0.99-0.8%$117.85$119.00$116.2181,400
$118.55+2.27+2.0%$117.44$121.02$115.07208,600
$116.28-1.29-1.1%$119.04$121.00$114.28203,300
$117.57+5.64+5.0%$110.21$118.00$110.2195,200
$111.93+0.040.0%$110.70$112.97$106.67141,900
$111.89-2.05-1.8%$112.85$113.99$109.14221,500
$113.94+0.22+0.2%$113.80$117.50$112.45142,800
$113.72+2.90+2.6%$111.26$114.75$108.22123,800
$110.82-0.54-0.5%$113.11$114.79$108.84133,188
$111.36+3.64+3.4%$106.99$113.47$104.48239,187
$107.72-3.16-2.8%$111.98$113.46$105.42176,400
$110.88-12.96-10.5%$122.01$122.60$110.84208,100

Splits

1 split · NASDAQ:MNPR · every price before a split is adjusted for it

DayRatioWhat
1-for-5Consolidation
Ticker
NASDAQ:MNPR
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Monopar Therapeutics Inc. news

Monopar Therapeutics Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
14 in the last 12 months · 137 in all · newest Nov 12, 2026 · oldest 2019
Decks
9 decks · latest Nov 8, 2026

Where Monopar Therapeutics Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:MNPR · Home listing · This pageNASDAQUnited StatesUSD
Tradegate:1IY0TradegateGermanyEUR
LS Exchange:A40JMLLS ExchangeGermanyEUR
gettex:1IY0gettexGermanyEUR
Lang & Schwarz:A40JMLLang & SchwarzGermanyEUR
BOATS:MNPRBOATSUnited StatesUSD
Frankfurt:1IY0FrankfurtGermanyEUR
Munich:1IY0MunichGermanyEUR
Stuttgart:1IY0StuttgartGermanyEUR

Valuation

Price/book 3.7× against a median of 2.5×: 8th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$362.8M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
3.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.18

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Monopar Therapeutics Inc. · NASDAQ:MNPRUS$467.6MUS$362.8Mn/an/an/a3.7×n/a0.0×1.18
TenNor Therapeutics Suzhou Ltd. Class H · HKEX:6872US$489.2MUS$391.6Mn/an/an/a5.0×n/a0.1×n/a
Crescent Biopharma, Inc. · NASDAQ:CBIOUS$482.9MUS$196.0Mn/a13.1×n/a1.8×−727.6%0.0×0.92
Sana Biotechnology, Inc. · NASDAQ:SANAUS$476.4MUS$408.5Mn/an/an/a2.6×n/a0.3×2.29
Regenxbio Inc. · NASDAQ:RGNXUS$473.4MUS$289.0Mn/a1.9×n/a3.2×−113.9%0.5×1.60
BlossomHill Therapeutics, Inc. · NASDAQ:BLSMUS$461.2MUS$259.4Mn/an/an/a2.2×n/a0.1×n/a
Neurogene Inc. · NASDAQ:NGNEUS$458.5MUS$106.4Mn/an/an/a1.3×n/a0.0×1.47
Assembly Biosciences, Inc. · NASDAQ:ASMBUS$454.4MUS$142.3Mn/a2.1×n/a1.5×−16.6%0.0×1.00
Shattuck Labs, Inc. · NASDAQ:STTKUS$454.2MUS$260.4Mn/an/an/a2.4×n/a0.0×1.10
G2GBIO, Inc. · KRX:456160US$449.1MUS$289.0Mn/a176×n/a4.3×−793.7%0.0×n/a
DiaMedica Therapeutics Inc. · NASDAQ:DMACUS$445.1MUS$410.4Mn/an/an/a15.5×n/a0.0×1.67
Median of the othersUS$459.9MUS$274.7M7.6×2.5×−420.7%0.0×1.47

Forecasts

8 strong buy · 4 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
129.92 USD · Analysts' mean
EPS, year to Dec 2026
-3.02 · 3 analysts

Team and board

Officers

OfficerRole
Chandler D. RobinsonCo-Founder, Chief Executive Officer and Board Member
Quan VuChief Financial Officer, Principal Accounting Officer, and Principal Financial Officer
Andrew CittadineChief Operating Officer
Jeffrey D. KentExecutive Vice President, Head of Medical Affairs
Christopher M. StarrCo-Founder and Executive Chairman of the Board
Patrice RiouxActing Chief Medical Officer
Susan RodriguezChief Commercial and Strategy Officer

Board

DirectorRole
Christopher M. StarrCo-Founder and Executive Chairman of the Board
Chandler D. RobinsonCo-Founder, Chief Executive Officer and Board Member
Kim R. TsuchimotoBoard Member
Lavina TalukdarBoard Member
Nicole SweenyBoard Member
Raymond W. AndersonBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · Before open+1.3%
Q2 2026Aug 12, 2026 · Before open+0.4%
Q1 2026May 15, 2026−7.8%
Q4 2025Mar 27, 2026 · After close−1.5%
Q3 2025Nov 13, 2025 · Before open+5.4%
Q2 2025Aug 12, 2025 · Before open+14.6%
Q1 2025May 13, 2025 · Before open−3.6%
Q4 2024Mar 26, 2025 · Before open+1.4%
Q3 2024Nov 8, 2024 · Before open+7.3%
Q2 2024Aug 9, 2024 · Before open−19.6%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · Before open−5.2%
Q4 2023Mar 28, 2024 · Before open−7.6%
Q3 2023Nov 9, 2023 · Before open−3.0%
Q2 2023Aug 10, 2023 · Before open+3.2%
Q1 2023May 11, 2023 · Before open−6.6%
Q4 2022Mar 23, 2023 · Before open+0.6%
Q3 2022Nov 10, 2022 · Before open−24.8%
Q2 2022Aug 11, 2022 · Before open+0.3%
Q1 2022May 12, 2022 · Before open−8.0%
Q4 2021Mar 24, 2022 · Before open−1.1%

Open Events

Decks

DeckKindSlidesDate
AASLD The Liver Meeting 2026Conference19 slidesNov 8, 2026
Investor Presentation (November 2026)Investor deck38 slidesNovember 2026
EASL Congress 2026Conference16 slidesMay 2026
Investor Presentation (May 2026)Investor deck37 slidesMay 2026
American Academy of Neurology (AAN) 2026Conference10 slidesApril 2026
AASLD 2025Conference26 slidesNovember 2025
ANA 2025Conference14 slidesSeptember 2025
EANM 2024Conference13 slidesOctober 2024
MASCC/ISOO Annual Meeting 2021Conference18 slidesJun 24, 2021

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue00000122.4K0000
Gross profit122.4K
Research and development9.90M13.0M5.60M7.59M6.49M4.07M1.97M1.77M935.3K280.4K
Selling, general and administrative6.80B3.16M3.23M2.95M2.63M2.44M2.36M1.63M1.17M912.5K
Operating income-16.7M-16.2M-8.83M-10.5M-9.13M-6.51M-4.32M-3.33M-16.6M-1.19M
Depreciation and amortization716.5M16.2M8.83M21.2K48.0K6.51M4.32K3.33M2.10M1.19M
EBITDA699.8M279-235-10.5M-9.08M0-4.32M0-14.5M0
Interest expense21.2K24.0K81.9K98.9K103.2K48.3K7.23K
Income before tax-13.7M-15.6M-8.40M-10.5M-9.10M-6.30M-4.22M-3.30M-16.6M-1.19M
Income tax800800800800018.4K0-70.8K-3.56K800
Net income-13.7M-15.6M-8.40M-10.5M-9.10M-6.30M-4.22M-3.23M-16.6M-1.19M
Earnings per share, basic-1.85-4.11-3.04-0.83-0.73-0.58-0.45-0.35-1.89
Earnings per share, diluted-0.73-0.58-0.45-0.35-1.89

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents61.8M45.8M7.27M8.19M20.3M16.7M13.2M6.89M8.98M2.07M
Short-term investments60.9M45.5M6.54M12.2M0
Current assets140.5M60.3M7.33M13.2M20.5M16.8M13.2M7.25M9.13M2.10M
Total assets140.7M60.3M7.35M13.2M20.5M16.9M13.4M7.32M9.93M2.90M
Accounts payable2.74M2.25M1.76M3.13M1.58M1.18M724.2K399.6K311.9K64.5K
Current liabilities2.74M5.25M1.76M3.13M1.58M1.18M724.2K399.6K311.9K64.5K
Total debt154.9K8.41K
Total liabilities2.89M5.25M1.76M3.14M1.58M1.18M724.2K399.6K311.9K64.5K
Shareholders' equity137.8M55.0M5.59M10.1M18.9M15.7M12.6M6.92M9.62M2.83M
Shares outstanding6.69M6.10M2.98M12.9M12.6M11.5M10.6M9.29M9.29M0

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-12.2M-6.40M-7.86M-7.23M-7.32M-4.66M-3.02M-2.68M-2.63M-1.19M
Capital spending00-30-1-40000
Free cash flow-12.2M-6.40M-7.86M-7.23M-7.32M-4.66M-3.02M-2.89M-2.63M-1.19M
Cash from investing-63.5M-14.3M4.93M-4.92M0
Cash from financing91.6M59.3M2.03M32.9K10.9M8.18M9.35M-206.3K9.54M1.26M
Share buybacks-35.0M0-47-77-638.18M10.3M4.71M1.26M
Change in cash16.0M38.6M-920.1K-12.1M3.57M3.52M6.32M-2.89M6.91M67.9K

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 27, 2026Big-stake noticeSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 2, 2026Insider tradeSEC
144 · Notice of proposed saleOct 1, 2026Other filingsSEC
4 · Change in ownershipSep 28, 2026Insider tradeSEC
144 · Notice of proposed saleSep 24, 2026Other filingsSEC
4/A · Change in ownership, amendedAug 28, 2026Insider tradeSEC
4/A · Change in ownership, amendedAug 28, 2026Insider tradeSEC
4 · Change in ownershipAug 27, 2026Insider tradeSEC
4 · Change in ownershipAug 27, 2026Insider tradeSEC
4 · Change in ownershipAug 27, 2026Insider tradeSEC
144 · Notice of proposed saleAug 26, 2026Other filingsSEC
144 · Notice of proposed saleAug 26, 2026Other filingsSEC
144 · Notice of proposed saleAug 25, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2026Big-stake noticeSEC
8-K · Current reportAug 12, 2026ResultsSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
S-8 POSJul 22, 2026Offer documentSEC
S-8 POSJul 22, 2026Offer documentSEC
S-8 POSJul 22, 2026Offer documentSEC
S-8 POSJul 22, 2026Offer documentSEC
S-8 · Registration statement for employee plansJul 22, 2026Offer documentSEC
8-K · Current reportJul 22, 2026Current reportSEC
144/A · Notice of proposed sale, amendedJul 10, 2026Other filingsSEC
144 · Notice of proposed saleJul 7, 2026Other filingsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 30, 2026Insider tradeSEC
8-K · Current reportJun 30, 2026Current reportSEC
8-K · Current reportJun 26, 2026Current reportSEC
8-K · Current reportJun 23, 2026Meeting outcomeSEC
8-K · Current reportMay 29, 2026Current reportSEC
8-K · Current reportMay 19, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 30, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 30, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
8-K · Current reportApr 20, 2026Current reportSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
10-K/A · Annual report, amendedApr 1, 2026Annual reportSEC
8-K · Current reportMar 27, 2026ResultsSEC
10-K · Annual reportMar 27, 2026Annual reportSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 4, 2026Insider tradeSEC
8-K · Current reportMar 2, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 6, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 30, 2026Big-stake noticeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
144 · Notice of proposed saleDec 19, 2025Other filingsSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 13, 2025ResultsSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025Current reportSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipSep 26, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 24, 2025Big-stake noticeSEC
8-K · Current reportSep 24, 2025Material contractSEC
424B5 · ProspectusSep 24, 2025Offer documentSEC
8-K · Current reportSep 15, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveSep 10, 2025Other filingsSEC
CORRESP · Letter to the SECSep 5, 2025Other filingsSEC
UPLOAD · Letter from the SECSep 4, 2025Other filingsSEC
S-3 · Registration statementAug 29, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
8-K · Current reportAug 12, 2025ResultsSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
UPLOAD · Letter from the SECJul 25, 2025Other filingsSEC
CORRESP · Letter to the SECJul 22, 2025Other filingsSEC
4 · Change in ownershipJul 16, 2025Insider tradeSEC
4 · Change in ownershipJul 16, 2025Insider tradeSEC
4 · Change in ownershipJul 16, 2025Insider tradeSEC
UPLOAD · Letter from the SECJul 16, 2025Other filingsSEC
144 · Notice of proposed saleJul 14, 2025Other filingsSEC
144 · Notice of proposed saleJul 14, 2025Other filingsSEC
144 · Notice of proposed saleJul 14, 2025Other filingsSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
8-K · Current reportJun 20, 2025Meeting outcomeSEC
DEFA14A · Additional proxy materialMay 23, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
ARS · Annual report to shareholdersMay 9, 2025Annual reportSEC
8-K · Current reportMay 7, 2025Current reportSEC
DEF 14A · Proxy statementApr 30, 2025Meeting noticeSEC
4 · Change in ownershipApr 4, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
144 · Notice of proposed saleApr 2, 2025Other filingsSEC
8-K · Current reportMar 31, 2025ResultsSEC
S-8 · Registration statement for employee plansMar 31, 2025Offer documentSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 6, 2025Insider tradeSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 5, 2025Insider tradeSEC
8-K · Current reportMar 3, 2025Management or board changeSEC
8-K · Current reportFeb 24, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 12, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 7, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveJan 28, 2025Other filingsSEC
424B3 · ProspectusJan 27, 2025Offer documentSEC
CORRESP · Letter to the SECJan 23, 2025Other filingsSEC
UPLOAD · Letter from the SECJan 22, 2025Other filingsSEC
S-3 · Registration statementJan 15, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 8, 2025Big-stake noticeSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
8-K · Current reportDec 23, 2024Material contractSEC
424B5 · ProspectusDec 23, 2024Offer documentSEC
424B3 · ProspectusDec 18, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 18, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedDec 17, 2024Big-stake noticeSEC
4 · Change in ownershipDec 17, 2024Insider tradeSEC
8-K · Current reportDec 6, 2024Current reportSEC
S-3 · Registration statementNov 29, 2024Offer documentSEC
8-K · Current reportNov 8, 2024ResultsSEC
10-Q · Quarterly reportNov 8, 2024Quarterly reportSEC
SC 13G · Big-stake noticeNov 6, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 31, 2024Big-stake noticeSEC
4 · Change in ownershipOct 30, 2024Insider tradeSEC
8-K · Current reportOct 30, 2024Material contractSEC
424B5 · ProspectusOct 29, 2024Offer documentSEC
424B5 · ProspectusOct 28, 2024Offer documentSEC
SC 13G · Big-stake noticeOct 28, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 24, 2024Big-stake noticeSEC
8-K · Current reportOct 24, 2024Acquisition or disposalSEC
8-K · Current reportOct 22, 2024Current reportSEC
8-K · Current reportOct 15, 2024Current reportSEC
8-K · Current reportOct 7, 2024Current reportSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
8-K · Current reportSep 12, 2024Current reportSEC
8-K · Current reportAug 27, 2024Current reportSEC
8-K · Current reportAug 21, 2024Current reportSEC
8-K · Current reportAug 14, 2024Current reportSEC
10-Q · Quarterly reportAug 9, 2024Quarterly reportSEC
8-K · Current reportAug 9, 2024ResultsSEC
ARS · Annual report to shareholdersJul 22, 2024Annual reportSEC
DEF 14A · Proxy statementJul 22, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementJul 11, 2024Meeting noticeSEC
8-K · Current reportJul 9, 2024Current reportSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
3 · Initial statement of ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
8-K · Current reportJun 11, 2024Current reportSEC
8-K · Current reportJun 10, 2024Current reportSEC
4 · Change in ownershipJun 5, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 30, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
8-K · Current reportMay 24, 2024Management or board changeSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC

This page holds 200 of 539 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Monopar Therapeutics Inc.’s releases · as of Oct 31, 2026

Common shares
6,776,773
Fully diluted
6,776,773

Fully diluted

LineSharesAs of
Common shares6,776,773Oct 31, 2026

Share count over time

CountShares
Oct 31, 20266,776,773

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Janus Henderson1.12M16.5%US$89.4MSep 30, 2026
Ra Capital Management, L.P.667K9.8%US$53.2MSep 30, 2026
BlackRock349K5.2%US$27.8MSep 30, 2026
Saturn V Capital Management LP312K4.6%US$24.9MSep 30, 2026
Vanguard294K4.3%US$23.4MSep 30, 2026
Siren, L.L.C.270K4.0%US$21.5MSep 30, 2026
State Street230K3.4%US$18.3MSep 30, 2026
Polar Capital Holdings Plc214K3.2%US$17MSep 30, 2026
Adage Capital Partners Gp, L.L.C.209K3.1%US$16.7MSep 30, 2026
TCG Crossover Management, LLC202K3.0%US$16.1MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
ADAR1 Capital Management, LLC179K2.6%US$14.3MSep 30, 2026
Balyasny Asset Management L.P.177K2.6%US$14.1MSep 30, 2026
Wellington174K2.6%US$13.8MSep 30, 2026
Deerfield Management Company, L.P.138K2.0%US$11MSep 30, 2026
Candriam S.C.A.130K1.9%US$10.4MSep 30, 2026
Geode Capital120K1.8%US$9.55MSep 30, 2026
Alyeska Investment Group, L.P.102K1.5%US$8.14MSep 30, 2026
Quadrature Capital Ltd92,4991.4%US$7.37MSep 30, 2026
Vivo Capital, LLC90,5001.3%US$7.21MSep 30, 2026
Goldman Sachs87,8771.3%US$7MSep 30, 2026
Ikarian Capital, LLC86,7611.3%US$6.91MSep 30, 2026
UBS85,2711.3%US$6.79MSep 30, 2026
Driehaus Capital Management LLC84,0401.2%US$6.7MSep 30, 2026
BNY74,8491.1%US$5.96MSep 30, 2026
Ameriprise50,8460.75%US$4.05MSep 30, 2026
Millennium48,6070.72%US$3.87MSep 30, 2026
Citadel47,8960.71%US$3.82MSep 30, 2026
Longaeva Partners L.P.45,7200.67%US$3.64MSep 30, 2026
Jane Street43,6830.64%US$3.48MSep 30, 2026
Woodline Partners LP42,9600.63%US$3.42MSep 30, 2026
Morgan Stanley38,0370.56%US$3.03MSep 30, 2026
Qube Research & Technologies Ltd37,2130.55%US$2.96MSep 30, 2026
Northern Trust35,1900.52%US$2.8MSep 30, 2026
Boothbay Fund Management, LLC26,0260.38%US$2.07MSep 30, 2026
DWS25,4610.38%US$2.03MSep 30, 2026
Hrt Financial LP23,3670.34%US$1.86MSep 30, 2026
Stempoint Capital LP23,3020.34%US$1.86MSep 30, 2026
Two Sigma16,6350.25%US$1.33MSep 30, 2026
XTX Topco Ltd15,9760.24%US$1.27MSep 30, 2026
D. E. Shaw & Co., Inc.14,7230.22%US$1.17MSep 30, 2026
Schwab13,9530.21%US$1.11MSep 30, 2026
Ishara Investments LP12,0000.18%US$956KSep 30, 2026
Bank of America10,6890.16%US$852KSep 30, 2026
Engineers Gate Manager LP10,3410.15%US$824KSep 30, 2026
Verdad Advisers, LP8,4090.12%US$670KSep 30, 2026
BNP Paribas8,0180.12%US$639KSep 30, 2026
Creative Planning7,9770.12%US$636KSep 30, 2026
Squarepoint Ops LLC7,7380.11%US$616KSep 30, 2026
State Of Wisconsin Investment Board7,3510.11%US$586KSep 30, 2026
ExodusPoint Capital Management, LP7,2770.11%US$580KSep 30, 2026

This page holds 50 of 103 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund160K2.4%US$14.8MJun 30, 2026
iShares Russell 2000 ETF119K1.8%US$11MJun 30, 2026
Fidelity Small Cap Index Fund49,3320.73%US$5.35MJul 31, 2026
Vanguard Extended Market Index Fund44,3110.65%US$4.1MJun 30, 2026
iShares Russell 2000 Value ETF31,7510.47%US$2.94MJun 30, 2026
Neuberger Small Cap Growth Fund25,3130.37%US$1.65MMay 31, 2026
BNY Mellon Small/Mid Cap Growth Fund23,8900.35%US$2.21MJun 30, 2026
Vanguard Russell 2000 Index Fund22,7280.34%US$1.48MMay 31, 2026
Fidelity Extended Market Index Fund20,4970.30%US$1.33MMay 31, 2026
Vanguard U.S. Momentum Factor ETF19,7670.29%US$1.29MMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
iShares Micro-Cap ETF15,1480.22%US$1.4MJun 30, 2026
Schwab Small-Cap Index Fund10,9530.16%US$1.19MJul 31, 2026
iShares Russell 2000 Growth ETF10,4650.15%US$969KJun 30, 2026
Master Small Cap Index Series7,7370.11%US$716KJun 30, 2026
Fidelity Total Market Index Fund7,1920.11%US$468KMay 31, 2026
Nuveen Small Cap Blend Index Fund5,9800.09%US$648KJul 31, 2026
Fidelity Series Total Market Index Fund5,9520.09%US$387KMay 31, 2026
Virtus Biotech Clinical Trials Etf5,2000.08%US$563KJul 31, 2026
EQ/2000 Managed Volatility Portfolio4,9140.07%US$455KJun 30, 2026
Fidelity Small Cap Value Index Fund4,7450.07%US$439KJun 30, 2026
Fidelity Nasdaq Composite Index Fund4,0950.06%US$266KMay 31, 2026
Vanguard Russell 2000 Growth Index Fund4,0920.06%US$266KMay 31, 2026
Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF3,1120.05%US$202KMay 31, 2026
LVIP State Street Small-Cap Index Fund3,0000.04%US$278KJun 30, 2026
Schwab Total Stock Market Index Fund3,0000.04%US$325KJul 31, 2026
Vanguard Balanced Index Fund2,6470.04%US$245KJun 30, 2026
EQ/Small Company Index Portfolio2,4300.04%US$225KJun 30, 2026
Small Cap Index Fund2,1900.03%US$203KJun 30, 2026
Global X Russell 2000 ETF2,1700.03%US$235KJul 31, 2026
Fidelity ZERO Total Market Index Fund2,1230.03%US$230KJul 31, 2026
Vanguard Institutional Total Stock Market Index Fund2,1050.03%US$195KJun 30, 2026
BNY Mellon Small Cap Multi-Strategy Fund1,8870.03%US$123KMay 31, 2026
Multi-Manager U.S. Small Cap Equity Fund1,8650.03%US$97,260Apr 30, 2026
Goldman Sachs Absolute Return Tracker Fund1,7240.03%US$160KJun 30, 2026
EQ/AB Small Cap Growth Portfolio1,6800.02%US$156KJun 30, 2026
ATM Small Cap Managed Volatility Portfolio1,6220.02%US$150KJun 30, 2026
Small Cap Index Fund1,5900.02%US$103KMay 31, 2026
MetLife Russell 2000 Index Portfolio1,5320.02%US$142KJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio1,5000.02%US$139KJun 30, 2026
Fidelity ZERO Extended Market Index Fund1,4520.02%US$157KJul 31, 2026
AQR Small Cap Momentum Style Fund1,4480.02%US$79,336Mar 31, 2026
Spectrum Fund1,3890.02%US$129KJun 30, 2026
Avantis U.S. Small Cap Equity ETF1,3180.02%US$85,723May 31, 2026
U.S. Small Cap Equity Fund1,2670.02%US$117KJun 30, 2026
Small-Cap Index Portfolio1,1840.02%US$110KJun 30, 2026
Fidelity Small Cap Growth Index Fund1,0580.02%US$97,960Jun 30, 2026
1290 VT Micro Cap Portfolio1,0090.01%US$93,423Jun 30, 2026
NVIT Small Cap Index Fund9320.01%US$86,294Jun 30, 2026
Small Cap Index Trust9220.01%US$85,368Jun 30, 2026
Goldman Sachs Small Cap Equity Insights Fund9200.01%US$99,682Jul 31, 2026

This page holds 50 of 98 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Tsuchimoto Kim R
Director
Sale1,295USD 70.75US$91,621Nov 4, 2026
Tsuchimoto Kim R
Director
Sale996USD 71.35US$71,065Nov 4, 2026
Tsuchimoto Kim R
Director
Sale600USD 72.21US$43,326Nov 4, 2026
Tsuchimoto Kim R
Director
Sale1,199USD 70.10US$84,050Nov 2, 2026
Anderson Raymond
Director
Sale840USD 66.16US$55,574Nov 2, 2026
Anderson Raymond
Director
Sale600USD 67.06US$40,236Nov 2, 2026
Anderson Raymond
Director
Sale200USD 68.68US$13,736Nov 2, 2026
Anderson Raymond
Director
Sale1,502USD 70.04US$105KNov 2, 2026
Starr Christopher M
Director
Sale4,631USD 78.09US$362KOct 1, 2026
Starr Christopher M
Director
Sale2,970USD 78.82US$234KOct 1, 2026
All 26 trades
TradeTradeSharesPriceValueDate
Starr Christopher M
Director
Sale799USD 79.67US$63,656Oct 1, 2026
Robinson Chandler
Director, Officer: Chief Executive Officer
Sale10,450USD 87.15US$911KSep 24, 2026
Robinson Chandler
Director, Officer: Chief Executive Officer
Sale9,638USD 87.96US$848KSep 24, 2026
Robinson Chandler
Director, Officer: Chief Executive Officer
Sale8,368USD 88.97US$745KSep 24, 2026
Robinson Chandler
Director, Officer: Chief Executive Officer
Sale600USD 89.79US$53,874Sep 24, 2026
Tsuchimoto Kim R
Director
Sale485USD 108.83US$52,783Aug 26, 2026
Tsuchimoto Kim R
Director
Sale615USD 109.56US$67,379Aug 26, 2026
Tsuchimoto Kim R
Director
Sale700USD 110.65US$77,455Aug 26, 2026
Tsuchimoto Kim R
Director
Sale1,098USD 111.84US$123KAug 26, 2026
Tsuchimoto Kim R
Director
Sale602USD 112.93US$67,984Aug 26, 2026
Tsuchimoto Kim R
Director
Sale590USD 113.84US$67,166Aug 26, 2026
Rioux Patrice
Other: Acting Chief Medical Officer
Sale1USD 111.26US$111Aug 26, 2026
Anderson Raymond
Director
Sale694USD 110.04US$76,368Aug 25, 2026
Anderson Raymond
Director
Sale646USD 111.07US$71,751Aug 25, 2026
Anderson Raymond
Director
Sale1,802USD 113.05US$204KAug 25, 2026
Anderson Raymond
Director
Sale646USD 110.07US$71,105Aug 25, 2026

Big stakes

StakeStakeSharesDateFiling
Janus Henderson Group PLC16.70%1.12MSep 30, 2026Schedule 13G
Hendricks Diane13.40%705KDec 9, 2024Schedule 13D
Ra Capital Management, L.P.9.90%668KDec 31, 2025Schedule 13G
AstraZeneca PLC7.80%523KDec 31, 2025Schedule 13G
BlackRock, Inc.5.03%338KSep 30, 2026Schedule 13G
Robinson Chandler4.50%307KJan 28, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Susan Rodriguez
Other companies: Avadel Pharmaceuticals PLC (Chief Operating Officer · Since at least May 13, 2025); Veradigm Inc. (Director · Since at least Feb 17, 2023); Heron Therapeutics, Inc. (Director · Sep 20, 2021 – Jan 31, 2025 · Past); Ardelyx, Inc. (Chief Commercial Officer · May 18, 2020 – May 21, 2024 · Past)
Chief Commercial and Strategy Officer · Since at least Mar 2, 2026
Nicole Sweeny
Other companies: KalVista Pharmaceuticals, Inc. (Chief Commercial Officer · Since at least Jun 18, 2025); Praxis Precision Medicines, Inc. (Chief Commercial Officer · Oct 15, 2020 – Feb 12, 2023 · Past)
Board Member · Since at least Jun 22, 2026
Quan Vu
Other companies: Ocugen, Inc. (CFO/CBO · Mar 6, 2023 – Mar 6, 2023 · Past); Forum Markets, Incorporated (COO / Chief Business Officer · Oct 29, 2021 – Dec 16, 2021 · Past)
Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer · Since at least Mar 3, 2025
Andrew Paul Mazar
Other companies: Actuate Therapeutics, Inc. (Chief Operating Officer · Since at least Aug 12, 2024)
Chief Scientific Officer, Director · Jan 8, 2018 – Mar 31, 2022 · Past
Christopher M. Starr
Other companies: Raptor Pharmaceutical Corp (Director · Sep 29, 2009 – Oct 24, 2016 · Past)
Co-Founder and Executive Chairman of the Board · Since at least Jan 8, 2018
Karthik Radhakrishnan
Other companies: Acer Therapeutics Inc (Chief Financial Officer · Mar 29, 2013 – Apr 8, 2015 · Past)
Chief Financial Officer · Jul 1, 2024 – Oct 28, 2024 · Past
Michael J. Brown
Other companies: Euronet Worldwide, Inc. (Chairman and CEO · Since at least Oct 13, 2023)
Director · Sep 30, 2023 – Dec 31, 2023 · Past
Raymond W. Anderson
Other companies: Raptor Pharmaceutical Corp (Director · Sep 29, 2009 – Oct 24, 2016 · Past)
Board Member · Since at least Jan 8, 2018
Andrew CittadineChief Operating Officer · Since at least Jun 1, 2021
Arthur J KlausnerDirector · Since at least Mar 31, 2022
All 17 people
PersonSeat
Chandler D. RobinsonChief Executive Officer, Director · Since at least Jan 8, 2018
Jeffrey D. KentExecutive Vice President, Head of Medical Affairs · Since at least Aug 19, 2026
Jose Octavio Pinto Costa FilhoChief Medical Officer · Jul 12, 2021 – Jul 12, 2021 · Past
Kim R. TsuchimotoBoard Member · Since at least Jan 8, 2018
Kirsten AndersonSVP, Clinical Development · Jan 8, 2018 – Jan 8, 2018 · Past
Lavina TalukdarDirector · Since at least Feb 21, 2025
Patrice RiouxActing Chief Medical Officer · Since at least Aug 27, 2026

Open People

Log in to ask 6ix AI your own questions about Monopar Therapeutics Inc.